Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Xyrem — Revenue from Contract with Customer, Excluding Assessed Tax

Other product segments

Xywav
$408.2M+18.4%
Epidiolex/Epidyolex
$249.8M+14.7%
Rylaze/Enrylaze
$103.7M+10.1%
Zepzelca
$101M+60.3%
Defitelio/defibrotide
$47.4M+16.5%
Modeyso
$41.4M—
High-sodium oxybate AG royalty revenue
$36.3M-25.8%
Vyxeos
$26.6M-9.8%
Ziihera
$13.3M+565%
Other royalty and contract revenues
$9.76M+27.5%
Other
$2.7M-73.8%

Similar metrics at other companies

Axsome Therapeutics logo
AXSMProduct — Revenue
$189.4M+57.4%
Roivant Sciences logo
ROIVProduct — Revenue
$18.37M+10.3%
Cytokinetics logo
CYTKNet Product Revenue — Revenue
$4.79M—
Ionis Pharmaceuticals logo
IONSProduct — Revenue
$42.96M+583%
BrightSpring Health Services, Inc. logo
BTSGProduct — Revenue
$3.17B+25.2%
Roivant Sciences logo
ROIVProduct revenue, net — Revenue, net
$0-100%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's xyrem — revenue from contract with customer, excluding assessed tax.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's xyrem — revenue from contract with customer, excluding assessed tax?
Jazz Pharmaceuticals (JAZZ) reported xyrem — revenue from contract with customer, excluding assessed tax of $31.2M in Q1 2026.
How has Jazz Pharmaceuticals's xyrem — revenue from contract with customer, excluding assessed tax changed year-over-year?
Jazz Pharmaceuticals's xyrem — revenue from contract with customer, excluding assessed tax decreased by 16.1% year-over-year, from $37.2M to $31.2M.
What is the long-term trend for Jazz Pharmaceuticals's xyrem — revenue from contract with customer, excluding assessed tax?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's xyrem — revenue from contract with customer, excluding assessed tax has grown at a -41.7% compound annual growth rate (CAGR), from $1.27B to $145.99M.
What does xyrem — revenue from contract with customer, excluding assessed tax mean?
The total net sales revenue earned from a specific drug product.
How do you interpret xyrem — revenue from contract with customer, excluding assessed tax?
An increase signals strong market adoption and growth, while a decrease suggests market saturation, generic erosion, or competitive displacement.
How does xyrem — revenue from contract with customer, excluding assessed tax compare across companies?
Standard revenue reporting metric across all biopharmaceutical companies for individual product lines.